ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)

臺大醫院;臺大醫院-內科部;臺大醫院-肝炎研究中心;Buti, M.M.ButiFlisiak, R.R.FlisiakRasenack, J.J.RasenackDavis, G.G.DavisAlberti, A.A.AlbertiGoeser, T.T.GoeserStanciu, C.C.StanciuChuang, W. -L.W. -L.ChuangTabak, F.F.TabakKao, J. -H.J. -H.KaoStreinu-Cercel, A.A.Streinu-CercelHofstetter, G.G.HofstetterWang, J.J.WangAvila, C.C.AvilaOrsenigo, R.R.Orsenigo2014-02-142018-07-112014-02-142018-07-112013http://ntur.lib.ntu.edu.tw//handle/246246/25969482 bytestext/htmlALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)http://ntur.lib.ntu.edu.tw/bitstream/246246/259694/1/index.html